Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210487

Enrollment

262

Registered

2021-12-16

Start date

2021-09-29

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Tumor

Interventions

Arm 1: Avelumab Arm 2: Avelumab, CPM 001, Utomilumab, PF-04518600 Arm 3: Avelumab, Lorlatinib Arm 4: Avelumab Arm 5: Avelumab, Pemetrexed Arm 6: Avelumab, Talazoparib Arm 7: Avelumab, Axitinib Arm 8:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1.Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study. 2.Participants must agree to follow the reproductive criteria. 3.Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1.Female participants who are pregnant or breastfeeding. 2.Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Primary Outcome Measures : 1.Number of participants with adverse events leading to permanent discontinuation of study intervention [ Time Frame: Baseline up to approximately 5 years ] 2.Number serious adverse events reported for all participants [ Time Frame: Baseline up to approximately 5 years ]	—

Countries

Australia, Belgium, Canada, Denmark, France, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Serbia, Spain, Taiwan, United Kingdom, United States

Contacts

Public ContactClinical Trials Information Desk

Pfizer R&D Japan G.K.

clinical-trials@pfizer.com+81-3-5309-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: May 29, 2026